Solubilization and Characterization of High and Low Affinity Pirenzepine Binding Sites from Rat Cerebral Cortex

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1985 Jul 1

PMID 4027484

Citations 5

Authors

C P Berrie

N J Birdsall

E C Hulme

M Keen

J M Stockton

Affiliations

Soon will be listed here.

Abstract

An apparently monomeric form of the digitonin-solubilized muscarinic acetylcholine receptor from the rat cerebral cortex retains a high affinity of 7 X 10(7) M-1 for pirenzepine. Muscarinic receptor binding sites in the rat cerebral cortex with a low affinity for pirenzepine are solubilized with relatively little change in affinity. The ability of pirenzepine to distinguish between subtypes of muscarinic binding site in the cerebral cortex is manifest in both the membrane-bound and soluble state.

Citing Articles

Acetylcholine.

Brown D Br J Pharmacol. 2006; 147 Suppl 1:S120-6.

PMID: 16402095 PMC: 1760728. DOI: 10.1038/sj.bjp.0706474.

The binding of pirenzepine to digitonin-solubilized muscarinic acetylcholine receptors from the rat myocardium.

Birdsall N, Hulme E, Keen M Br J Pharmacol. 1986; 87(2):307-16.

PMID: 3754173 PMC: 1916543. DOI: 10.1111/j.1476-5381.1986.tb10819.x.

Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex.

Adem A, Sabbagh M, Nordberg A J Neural Transm. 1988; 72(1):11-8.

PMID: 3379385 DOI: 10.1007/BF01244628.

Pharmacological characterization of the physostigmine stimulus in rats.

Jung M, Perio A, Worms P, Soubrie P Psychopharmacology (Berl). 1988; 95(4):553-5.

PMID: 3145526 DOI: 10.1007/BF00172975.

Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes.

Pedder E, Eveleigh P, Poyner D, Hulme E, Birdsall N Br J Pharmacol. 1991; 103(2):1561-7.

PMID: 1884110 PMC: 1908365. DOI: 10.1111/j.1476-5381.1991.tb09827.x.

References

Birdsall N, BURGEN A, Hulme E . The binding of agonists to brain muscarinic receptors. Mol Pharmacol. 1978; 14(5):723-36. View

Berrie C, Birdsall N, Hulme E, Keen M, Stockton J . Solubilization and characterization of guanine nucleotide-sensitive muscarinic agonist binding sites from rat myocardium. Br J Pharmacol. 1984; 82(4):853-61. PMC: 1986921. DOI: 10.1111/j.1476-5381.1984.tb16482.x. View

Hammer R, Berrie C, Birdsall N, BURGEN A, Hulme E . Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature. 1980; 283(5742):90-2. DOI: 10.1038/283090a0. View

Brown D, Forward A, Marsh S . Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol. 1980; 71(2):362-4. PMC: 2044477. DOI: 10.1111/j.1476-5381.1980.tb10948.x. View

Hulme E, Berrie C, Birdsall N, BURGEN A . Two populations of binding sites for muscarinic antagonists in the rat heart. Eur J Pharmacol. 1981; 73(2-3):137-42. DOI: 10.1016/0014-2999(81)90085-6. View

Hammer R . Subclasses of muscarinic receptors and pirenzepine. Further experimental evidence. Scand J Gastroenterol Suppl. 1982; 72:59-67. View

Watson M, Roeske W, Yamamura H . [3h]pirenzepine selectively identifies a high affinity population of muscarinic cholinergic receptors in the rat cerebral cortex. Life Sci. 1982; 31(18):2019-23. DOI: 10.1016/0024-3205(82)90041-8. View

Hammer R, Giachetti A . Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 1982; 31(26):2991-8. DOI: 10.1016/0024-3205(82)90066-2. View

Caulfield M, Higgins G, Straughan D . Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. J Pharm Pharmacol. 1983; 35(2):131-2. DOI: 10.1111/j.2042-7158.1983.tb04290.x. View

10.

Watson M, Yamamura H, Roeske W . A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci. 1983; 32(26):3001-11. DOI: 10.1016/0024-3205(83)90652-5. View

11.

Birdsall N, Hulme E, Stockton J, BURGEN A, Berrie C, Hammer R . Muscarinic receptor subclasses: evidence from binding studies. Adv Biochem Psychopharmacol. 1983; 37:323-9. View

12.

Hulme E, Berrie C, Birdsall N, Jameson M, Stockton J . Regulation of muscarinic agonist binding by cations and guanine nucleotides. Eur J Pharmacol. 1983; 94(1-2):59-72. DOI: 10.1016/0014-2999(83)90442-9. View

13.

Watson M, Roeske W, Johnson P, Yamamura H . [3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia. Brain Res. 1984; 290(1):179-82. DOI: 10.1016/0006-8993(84)90751-0. View

14.

Roeske W, Venter J . The differential loss of [3H]pirenzepine vs [3H] (-) quinuclidinylbenzilate binding to soluble rat brain muscarinic receptors indicates that pirenzepine binds to an allosteric state of the muscarinic receptor. Biochem Biophys Res Commun. 1984; 118(3):950-7. DOI: 10.1016/0006-291x(84)91487-6. View

15.

Luthin G, Wolfe B . Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J Pharmacol Exp Ther. 1984; 228(3):648-55. View

16.

Berrie C, Birdsall N, Haga K, Haga T, Hulme E . Hydrodynamic properties of muscarinic acetylcholine receptors solubilized from rat forebrain. Br J Pharmacol. 1984; 82(4):839-51. PMC: 1986934. DOI: 10.1111/j.1476-5381.1984.tb16481.x. View

17.

Hulme E, Birdsall N, BURGEN A, Mehta P . The binding of antagonists to brain muscarinic receptors. Mol Pharmacol. 1978; 14(5):737-50. View